MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 340-347

  Jessen, Walter J ^a,f   Miller, Shyra J ^a   Jousma, Edwin ^a   Wu, Jianqiang ^a   Rizvi, Tilat A ^a   Brundage, Meghan E ^a   Eaves, David ^a   Widemann, Brigitte ^b   Kim, Mi Ok ^a   Dombi, Eva ^b   Sabo, Jessica ^b   Dudley, Atira Hardiman ^a   Niwa Kawakita, Michiko ^c   Page, Grier P ^d   Giovannini, Marco ^e   Aronow, Bruce J ^a   Cripe, Timothy P ^a   Ratner, Nancy ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSERM   (France)

^d RTI INTERNATIONAL   (United States)

^e HOUSE EAR INSTITUTE   (United States)

^f Biomarker Center of Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAF PROTEIN; RAS PROTEIN; SPROUTY 4 PROTEIN; SPROUTY PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NEGATIVE FEEDBACK; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; DIPHENYLAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM TRANSPLANTATION; NEUROFIBROMATOSIS 1; ONCOGENE PROTEIN P21(RAS); PERIPHERAL NERVOUS SYSTEM NEOPLASMS; RAF KINASES; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873809147     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60578     Document Type: Article

References (63)

1. Theos A, Korf BR. Pathophysiology of neurofibromatosis type 1. Ann Intern Med. 2006;144(11): 842-849.
2. De Raedt T, et al. Somatic loss of wild type NF1 allele in neurofibromas: comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer. 2006;45(10): 893-904.
3. Carli M, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005; 23(33): 8422-8430.
4. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5): 311-314.
5. Friedrich RE, Hartmann M, Mautner VF. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. Anticancer Res. 2007; 27(4A): 1957-1960.
6. McCaughan JA, Holloway SM, Davidson R, Lam WW. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet. 2007;44(7): 463-466.
7. Huson SM, et al. Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A. 2011; 155A(2): 307-321.
8. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia. 2008; 56(14): 1590-1605.
9. McCormick F. Ras signaling and NF1. Curr Opin Genet Dev. 1995;5(1): 51-55.
10. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007;26(32): 4609-4616.
11. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem. 2000; 275(39): 30740-30745.
12. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992; 356(6371): 663-664.
13. DeClue JE, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (Type 1) neurofibromatosis. Cell. 1992;69(2): 265-273.
14. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1): 11-22.
15. Collado M, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005; 436(7051):642.
16. Narita M, Lowe SW. Senescence comes of age. Nat Med. 2005;11(9): 920-922.
17. Courtois-Cox S, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 2006;10(6): 459-472.
18. Cox AD, Der CJ. Ras history: the saga continues. Small Gtpases. 2010;1(1): 2-27.
19. Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009;11:e30.
20. Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet. 1999;89(1): 14-22.
21. Bodempudi V, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009; 29(14): 3964-3974.
22. Johansson G, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008;7(5): 1237-1245.
23. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102(24): 8573-8578.
24. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002; 296(5569): 920-922.
25. Wu J, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008; 13(2): 105-116.
26. Zheng H, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell. 2008;13(2): 117-128.
27. Joseph NM, et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell. 2008;13(2): 129-140.
28. Gitler AD, et al. Nf1 has an essential role in endothelial cells. Nat Genet. 2003;33(1): 75-79.
29. Yang FC, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kitdependent bone marrow. Cell. 2008;135(3): 437-448.
30. Wu J, et al. Preclincial testing of Sorafenib and RAD001 in the Nf(flox/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2012; 58(2): 173-180.
31. Solomon J, Warren K, Dombi E, Patronas N, Widemann B. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph. 2004;28(5): 257-265.
32. Dombi E, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007;68(9): 643-647.
33. Chang T, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. doi:10.1172/JCI63193.
34. Miller SJ, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009; 1(4): 236-248.
35. Haura EB, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8): 2450-2457.
36. LoRusso PM, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6): 1924-1937.
37. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408(3): 297-315.
38. Sebolt-Leopold JS, Herrera R. Targeting the mitogen- activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12): 937-947.
39. Mahller YY, Rangwala F, Ratner N, Cripe TP. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer. 2006; 46(7): 745-754.
40. Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074): 358-362.
41. Patel AV, et al. Ras-driven transcriptome analysis identifies aurora kinase a as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 2012;18(18): 5020-5030.
42. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011;68(2): 547-552.
43. Wu J, et al. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2012;58(2): 173-180.
44. Ciuffreda L, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009;11(8): 720-731.
45. Sweet-Cordero A, et al. An oncogenic KRAS2 expression signature identified by cross-species geneexpression analysis. Nat Genet. 2005;37(1): 48-55.
46. Pratilas CA, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106(11): 4519-4524.
47. Jakacki RI, et al. Phase I trial of pegylated interferon- alpha-2b in young patients with plexiform neurofibromas. Neurology. 2011;18(3): 265-272.
48. Robertson KA, et al. Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas. J Clin Oncol. 2011; 29(suppl; abstract 10030).
49. Mattingly RR, et al. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther. 2006;316(1): 456-465.
50. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011;2(3): 359-372.
51. Sos ML, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009;106(43): 18351-18356.
52. Gioeli D, et al. Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther. 2011;10(9): 1581-1590.
53. Lauchle JO, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009;461(7262): 411-414.
54. Lyubynska N, et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011;3(76):76ra27.
55. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature. 2006; 441(7092): 457-462.
56. Rauen KA, et al. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011;157(2): 136-146.
57. Masica DL, Karchin R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res. 2011;71(13): 4550-4561.
58. Ding L, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216): 1069-1075.
59. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353): 609-615.
60. Mahller YY, et al. Tissue inhibitor of metalloproteinase- 3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 2008; 68(4): 1170-1179.
61. Brown AP, Carlson TC, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007;59(5): 671-679.
62. Liu C, Cripe TP, Kim MO. Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther. 2010; 18(9): 1724-1730.
63. Miller SJ, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006;66(5): 2584-2591.